| Related Articles |
Time-to-onset and -resolution of adverse events before/after atomoxetine discontinuation in adult patients with ADHD.
Postgrad Med. 2015 Sep 2;:1-9
Authors: Upadhyaya H, Tanaka Y, Lipsius S, Kryzhanovskaya LA, Lane JR, Escobar R, Trzepacz PT, Allen AJ
Abstract
BACKGROUND: Adults with attention-deficit/hyperactivity disorder treated with atomoxetine were examined for time-to-onset and -resolution of common treatment-emergent adverse events (TEAEs) and male sexual dysfunction, and for changes in blood pressure (BP) and heart rate (HR) upon atomoxetine discontinuation.
METHODS: 12-week open-label atomoxetine (40-100 mg/day) was followed by 12-week double-blind maintenance treatment (atomoxetine 80 or 100 mg/day). Responders were then randomized to atomoxetine (n = 266) or placebo (n = 258) for 25-week randomized withdrawal. Examined were (1) median time-to-onset and -resolution of TEAEs during atomoxetine treatment, and (2) within group, visitwise mean changes for sitting HR, systolic BP, and diastolic BP for the postrandomization placebo group.
RESULTS: Common adverse events (AEs) appeared early, within week 1 of atomoxetine treatment. Some AEs resolve relatively rapidly, whereas others have a more lingering course of resolution (including male sexual side effects); median resolution times were 3 – 53 days. BP and HR increases during atomoxetine treatment returned to baseline upon atomoxetine discontinuation.
CONCLUSION: Atomoxetine is associated with common AEs, with 3- to 53-day median resolution times.
TRIAL REGISTRATION: ClincialTrials.gov – NCT00700427.
PMID: 26329980 [PubMed – as supplied by publisher]
